|Bid||9,895.00 x 0|
|Ask||9,897.00 x 0|
|Day's range||9,831.00 - 10,046.00|
|52-week range||8,090.32 - 11,540.00|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||45.39|
|Forward dividend & yield||2.22 (1.93%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
WILMINGTON, Del., September 16, 2022--A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) showed positive high-level results in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).
WILMINGTON, Del., September 15, 2022--Today, AstraZeneca (Nasdaq: AZN) launched Up The Antibodies, an important new campaign that embraces the reality for millions of immunocompromised Americans1,2: COVID-19 isn’t over. While it feels like life has gone back to normal for many, this community still has very real cause for concern. Now, an added layer of COVID-19 protection can help people who are immunocompromised start to get back out into the world, doing what they love with whom they love.
WILMINGTON, Del., September 12, 2022--Updated results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival (OS) benefit as a treatment for patients with advanced biliary tract cancer (BTC).